Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
Genetic toxicity (mutagenicity) in bacteria in vitro
A bacterial gene mutation assay (Ames test) was performed with Amides, C18, branched and linear according to OECD TG 471 (Bowles, 2003). The strains Salmonella typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102 were tested in two repetitions (triplicates each) at concentrations from 0.15 to 5000 µg/mL (vehicle: DMSO) in the preliminary toxicity test, and at concentrations from 50 to 5000 µg/mL (-/+ S9) (vehicle: DMSO) in the mutation test. No increase in the number of revertant colonies was noted in any of the bacterial strains, with and without metabolic activation system. Cytotoxicity was observed in a preliminary toxicity test at concentrations at 5000 µg/plate. Thus, 5000 µg/plate was the highest concentration used in this test with and without metabolic activation. The included positive and negative/vehicle controls showed the expected results. Under the conditions of the study, the test substance did not induce mutations in the bacterial gene mutation assay in the absence and presence of a metabolic activation system in any of the strains tested.
Genetic toxicity (chromosome aberration) in human lymphocytes in vitro
An in vitro chromosome aberration test in human lymphocytes was performed with Amides, C18, branched and linear according to OECD TG 473 (Wright, 2003). Human lymphocytes of fresh heparinized whole blood from peripheral circulation of a volunteer were tested in two repetitions at concentrations from 19.53 to 5000 µg/mL (vehicle: DMSO) in the preliminary toxicity test, at concentrations from 9.77 to 312.5 µg/mL (-/+ S9) (vehicle: DMSO) and at concentrations from 9.77 to 312.5 µg/mL (- S9) and 4.88 to 78.13 µg/mL (+ S9) in the aberration test. No significant increase in the number of polyploid and aberrant cells was noted in any of the tested concentrations with and without metabolic activation system. Cytotoxicity was observed in the first experiment at concentrations at 78.13 µg/mL (- S9) and 156.25 µg/mL (+ S9) and in the second experiment at concentrations at 19.53 µg/mL (- S9) and 39.06 µg/mL (+ S9). Precipitation of the test material was observed at a concentration of 156.25 µg/mL. Under the conditions of the study, the test substance did not induce polyploid and aberrant cells in the chromosome aberration test in human lymphocytes in absence and presence of a metabolic activation system.
Genetic toxicity (mammalian erythrocyte micronucleus assay) in vivo
An in vivo mammalian erythrocyte micronucleus assay was performed with Amides, C18, branched and linear according to OECD TG 474 and in compliance with GLP (Flanders, 2014).The test material was administered via single intraperitoneal application to 7 male Albino mice of each dose group at nominal concentrations of 100, 200, and 400 mg/kg bw. Bone marrow cells of mice from each dose level were freshly isolated 24 hours post-application. In addition, a second group dosed with the test item at 400 mg/kg bw was killed 48 hours post-application. The ratio of polychromatic erythrocytes (PCE) and normochromatic erythrocytes (NCE) was determined by counting and differentiating isolated and fixed erythrocytes. Appropriate negative (7 males, arachis oil) and positive controls (5 males, 50 mg/kg bw cyclophosphamide) were included in the study and showed the expected result. No statistically significant increase in the frequency of micronucleated polychromatic erythrocytes was observed in the 48 or 24-hour 400 mg/kg bw test item dose groups, or the 24-hour 200 mg/kg bw dose group. A very modest, but statistically significant, increase was observed in the 24-hour 100 mg/kg bw test item dose group when compared to the vehicle control group. However, this finding was considered to be artefactual and of no toxicological significance. Based on the results of the study the test substance is negative for the induction of micronuclei under the conditions of the test.
Justification for selection of genetic toxicity endpoint
No study was selected, since the available studies address different relevant types of genetic toxicity, and all available in vitro and in vivo genetic toxicity studies were negative.
Short description of key information:
In vitro genotoxicity:
Bacterial reverse mutation assay (Ames test / OECD guideline 471): negative
In vitro chromosome aberration test in human lymphocytes (CA / OECD guideline 473): negative
In vivo genotoxicity:
Micronucleus assay (OECD guideline 474): negative
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
The available data on genetic toxicity of Amides, C18, branched and linear do not meet the criteria for classification according to Regulation (EC) No 1272/2008 or Directive 67/548/EEC and are therefore conclusive but not sufficient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.